(LXU) Lsb Industries - Overview
Stock: Ammonia, Ammonium Nitrate, Urea, Nitric Acid, Sulfuric Acid
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 47.4% |
| Relative Tail Risk | -8.71% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.58 |
| Alpha | 4.30 |
| Character TTM | |
|---|---|
| Beta | 1.209 |
| Beta Downside | 1.792 |
| Drawdowns 3y | |
|---|---|
| Max DD | 65.68% |
| CAGR/Max DD | -0.10 |
Description: LXU Lsb Industries December 26, 2025
L S B Industries, Inc. (NYSE: LXU) manufactures and markets a broad portfolio of nitrogen-based chemicals-including ammonia, ammonium nitrate (both fertilizer-grade and industrial-grade), urea-ammonia nitrate, sulfuric and nitric acids, carbon dioxide, and specialty ammonia solutions-serving agricultural, industrial, defense, and specialty-chemical end-markets across the United States. Founded in 1968 and headquartered in Oklahoma City, the company sells primarily to farmers, fertilizer dealers, industrial acid users, and explosives manufacturers.
Key operating metrics from the most recent filing (FY 2023) show revenue of roughly $1.2 billion, a modest EBITDA margin of ~6 % and net income of $45 million, reflecting the capital-intensive nature of the business and exposure to volatile nitrogen commodity prices. The firm’s earnings are closely tied to three macro drivers: (1) global grain price trends that influence fertilizer demand, (2) regulatory pressure on nitrogen emissions that can both constrain supply and create premium pricing for low-NOx products, and (3) seasonal agricultural cycles that dictate production scheduling and inventory levels. Compared with the broader Diversified Chemicals sub-industry, LXU’s revenue growth of 3 % YoY lags the sector average of 5 % but its cash conversion cycle is tighter (≈45 days vs. industry ~55 days), indicating relatively efficient working-capital management.
For a deeper quantitative view of LXU’s valuation and risk profile, you may want to explore the ValueRay platform.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: -668.0k TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA -1.01 > 1.0 |
| NWC/Revenue: 29.97% < 20% (prev 36.51%; Δ -6.54% < -1%) |
| CFO/TA 0.07 > 3% & CFO 81.6m > Net Income -668.0k |
| Net Debt (458.4m) to EBITDA (111.9m): 4.09 < 3 |
| Current Ratio: 2.84 > 1.5 & < 3 |
| Outstanding Shares: last quarter (71.8m) vs 12m ago 0.23% < -2% |
| Gross Margin: 11.82% > 18% (prev 0.10%; Δ 1172 % > 0.5%) |
| Asset Turnover: 50.17% > 50% (prev 43.97%; Δ 6.20% > 0%) |
| Interest Coverage Ratio: 0.96 > 6 (EBITDA TTM 111.9m / Interest Expense TTM 31.5m) |
Altman Z'' 2.15
| A: 0.15 (Total Current Assets 270.6m - Total Current Liabilities 95.3m) / Total Assets 1.15b |
| B: 0.19 (Retained Earnings 216.1m / Total Assets 1.15b) |
| C: 0.03 (EBIT TTM 30.1m / Avg Total Assets 1.17b) |
| D: 0.35 (Book Value of Equity 225.3m / Total Liabilities 644.9m) |
| Altman-Z'' Score: 2.15 = BBB |
Beneish M -3.25
| DSRI: 0.94 (Receivables 46.6m/44.3m, Revenue 585.1m/520.1m) |
| GMI: 0.87 (GM 11.82% / 10.34%) |
| AQI: 0.87 (AQ_t 0.00 / AQ_t-1 0.00) |
| SGI: 1.12 (Revenue 585.1m / 520.1m) |
| TATA: -0.07 (NI -668.0k - CFO 81.6m) / TA 1.15b) |
| Beneish M-Score: -3.25 (Cap -4..+1) = AA |
What is the price of LXU shares?
Over the past week, the price has changed by +8.74%, over one month by +6.99%, over three months by +7.57% and over the past year by +17.47%.
Is LXU a buy, sell or hold?
- StrongBuy: 3
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the LXU price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11.2 | 12.1% |
| Analysts Target Price | 11.2 | 12.1% |
| ValueRay Target Price | 10.2 | 2.1% |
LXU Fundamental Data Overview February 05, 2026
P/S = 1.1571
P/B = 1.3416
P/EG = -0.24
Revenue TTM = 585.1m USD
EBIT TTM = 30.1m USD
EBITDA TTM = 111.9m USD
Long Term Debt = 447.6m USD (from longTermDebt, last quarter)
Short Term Debt = 2.20m USD (from shortTermDebt, last quarter)
Debt = 486.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 458.4m USD (from netDebt column, last quarter)
Enterprise Value = 1.14b USD (677.0m + Debt 486.4m - CCE 28.0m)
Interest Coverage Ratio = 0.96 (Ebit TTM 30.1m / Interest Expense TTM 31.5m)
EV/FCF = -380.9x (Enterprise Value 1.14b / FCF TTM -2.98m)
FCF Yield = -0.26% (FCF TTM -2.98m / Enterprise Value 1.14b)
FCF Margin = -0.51% (FCF TTM -2.98m / Revenue TTM 585.1m)
Net Margin = -0.11% (Net Income TTM -668.0k / Revenue TTM 585.1m)
Gross Margin = 11.82% ((Revenue TTM 585.1m - Cost of Revenue TTM 515.9m) / Revenue TTM)
Gross Margin QoQ = 16.43% (prev 15.32%)
Tobins Q-Ratio = 0.99 (Enterprise Value 1.14b / Total Assets 1.15b)
Interest Expense / Debt = 1.51% (Interest Expense 7.36m / Debt 486.4m)
Taxrate = 26.28% (2.54m / 9.65m)
NOPAT = 22.2m (EBIT 30.1m * (1 - 26.28%))
Current Ratio = 2.84 (Total Current Assets 270.6m / Total Current Liabilities 95.3m)
Debt / Equity = 0.96 (Debt 486.4m / totalStockholderEquity, last quarter 504.6m)
Debt / EBITDA = 4.09 (Net Debt 458.4m / EBITDA 111.9m)
Debt / FCF = -153.8 (out of range, set to none) (Net Debt 458.4m / FCF TTM -2.98m)
Total Stockholder Equity = 495.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.06% (Net Income -668.0k / Total Assets 1.15b)
RoE = -0.13% (Net Income TTM -668.0k / Total Stockholder Equity 495.7m)
RoCE = 3.20% (EBIT 30.1m / Capital Employed (Equity 495.7m + L.T.Debt 447.6m))
RoIC = 2.29% (NOPAT 22.2m / Invested Capital 970.2m)
WACC = 6.50% (E(677.0m)/V(1.16b) * Re(10.37%) + D(486.4m)/V(1.16b) * Rd(1.51%) * (1-Tc(0.26)))
Discount Rate = 10.37% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.87%
Fair Price DCF = unknown (Cash Flow -2.98m)
EPS Correlation: -61.48 | EPS CAGR: -23.83% | SUE: -0.60 | # QB: 0
Revenue Correlation: -65.73 | Revenue CAGR: -5.24% | SUE: 2.55 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.16 | Chg30d=+0.040 | Revisions Net=+2 | Analysts=2
EPS next Year (2026-12-31): EPS=0.40 | Chg30d=-0.018 | Revisions Net=-1 | Growth EPS=-8.0% | Growth Revenue=-1.1%